In addition, researchers have explored the development of CD40 × HER2 bispecific antibodies (bsAbs), which possess CD40-targeted macrophage co-stimulatory activity and HER2-mediated anti-tumor activity, with limited immune-related adverse events (irAEs), offering a partial solution to trastuzumab resistance in GC [35]. Here, ERBB2 is linked to neoplasm.